Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2022-04-21 Interim / Quarterly Rep…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 13 pages 3.2MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities & Cash Report and 4C For the quarter ended 31 March 2022' and is an ASX announcement. It contains detailed information about clinical trial progress, patent grants, financial updates including cash flow, research and development expenditure, and management appointments. The presence of the Appendix 4C (quarterly cash flow report) and detailed financial and operational data for a quarter indicates this is a comprehensive quarterly report. It is not merely an announcement of a report but contains substantive financial and operational data for the quarter ended 31 March 2022. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2022
2022-04-21 English
First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc 3 pages 131.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited about dosing the first patient in a Phase I clinical trial of an oncolytic virotherapy candidate. It provides detailed information about the clinical trial, the drug candidate, and company background. There are no financial statements, earnings data, or regulatory filings related to financial performance. The content is a corporate announcement about a clinical trial milestone, not a financial report, management change, or shareholder vote. Therefore, it fits best under the category of a general regulatory announcement or corporate update. Given the absence of a more specific category, the appropriate classification is Regulatory Filings (RNS). The document length (6659 characters) and detailed content support this classification with high confidence.
2022-04-12 English
Release of Securities from Escrow 1 page 97.7KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement regarding the release of shares from escrow, referencing ASX listing rule 3.10A. It is a regulatory announcement about share capital status but does not detail a financial report or results. The document is short (633 characters) and is an announcement of a capital event related to shares. This fits best under Share Issue/Capital Change (SHA) as it concerns changes in share status (release from escrow).
2022-04-11 English
Application for quotation of securities - IMU 9 pages 32.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and prices. This type of document is an announcement related to changes in the company's capital structure, specifically the issuance and quotation of new shares resulting from option exercises. It is not a financial report, earnings release, or management discussion. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2022-03-31 English
Dose Escalation in Phase 1 Clinical Trial of CHECKvacc 3 pages 118.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited regarding the progression of a Phase I clinical trial dose escalation for their oncolytic virotherapy candidate CHECKvacc. It provides details about the clinical trial, safety data, and future plans but does not contain financial statements, earnings data, or regulatory certifications. The content is a corporate announcement about clinical trial progress rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information about the trial progress, not just a notice of report availability. Therefore, the document fits best into the category of a general regulatory announcement about clinical trial progress, which falls under Regulatory Filings (RNS).
2022-03-23 English
Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia 4 pages 117.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited about receiving ethics approval to start a Phase I clinical trial of a new cancer oncolytic virotherapy in the USA. It details the clinical trial's purpose, sites, investigators, and background information about the company and the trial. There are no financial statements, earnings data, or detailed financial analysis. The document is a regulatory announcement about a clinical trial approval, not a financial report or management discussion. It is not a report publication announcement since it contains substantive information about the trial start. The content fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about clinical trial approval and commencement.
2022-03-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.